Vertex EVP Tatsis sells 1,500 company shares

Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions involving company common shares.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Ourania Tatsis reported two stock transactions involving company common shares. On February 13, 2026, she disposed of 3,804 shares in a tax-withholding transaction at $487.76 per share and completed an open-market sale of 1,500 shares at a weighted average price of $499.99 per share.

The open-market sale was made under a company-approved Rule 10b5-1 trading plan entered into on August 21, 2025. Following these transactions, she directly owned 46,132 shares of Vertex common stock.

Insider Trade Summary

Net Seller: 1,500 shares

Net Sell 2 txns

Insider Tatsis Ourania

Role EVP, Chief Reg. & Quality Off.

Sold 1,500 shs ($750K)

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,804	$487.76	$1.86M
Sale	Common Stock	1,500	$499.99	$750K

Holdings After Transaction: Common Stock — 46,132 shares (Direct)

Footnotes (3)

1. F1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.
2. F2. Open market sales reported on this line occurred at a weighted average price of $499.99 (range $499.99 to $500.04).
3. F3. Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Vertex (VRTX) executive Ourania Tatsis report?

Ourania Tatsis reported two stock transactions in Vertex common shares. She disposed of 3,804 shares to cover tax obligations and sold 1,500 shares in an open-market transaction, both on February 13, 2026, as disclosed in the Form 4 filing.

How many Vertex (VRTX) shares did Ourania Tatsis sell in the open market?

She sold 1,500 Vertex common shares in an open-market transaction. The sale occurred on February 13, 2026, at a weighted average price of $499.99 per share, with individual prices ranging from $499.99 to $500.04, as detailed in the Form 4 footnotes.

At what prices did the Vertex (VRTX) insider transactions by Ourania Tatsis occur?

The transactions occurred at prices near $500 per share. The tax-withholding disposition involved 3,804 shares at $487.76 per share, while the 1,500-share open-market sale had a weighted average price of $499.99, within a range of $499.99 to $500.04.

Was the Vertex (VRTX) stock sale by Ourania Tatsis under a Rule 10b5-1 plan?

Yes, the open-market sale was executed under a Rule 10b5-1 trading plan. The filing states it was made under a company-approved plan entered into on August 21, 2025, providing a prearranged framework for selling shares at a later date.

How many Vertex (VRTX) shares does Ourania Tatsis own after these transactions?

After the reported transactions, she directly owned 46,132 Vertex shares. This figure reflects her holdings following the February 13, 2026 tax-withholding disposition of 3,804 shares and the separate open-market sale of 1,500 shares disclosed in the Form 4.

What was the purpose of the 3,804-share disposition by Vertex (VRTX) executive Ourania Tatsis?

The 3,804-share disposition was for tax withholding. The Form 4 classifies this as a tax-withholding transaction, where shares are delivered to satisfy tax liabilities associated with equity compensation, rather than a discretionary open-market sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/18/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tatsis Ourania

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Reg. & Quality Off.

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		F		3,804	D	$487.76	47,632	D
Common Stock	02/13/2026		S(1)		1,500	D	$499.99(2)(3)	46,132	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

2. Open market sales reported on this line occurred at a weighted average price of $499.99 (range $499.99 to $500.04).

3. Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.